Prof. Dr. med. et phil. nat. Markus Jörger
Oberarzt Onkologie/Hämatologie
Mitarbeiter Wissenschaftliche Module CTU (Klinische Pharmakologie)
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
Klopp-Schulze L, Jörger M, Wicha S, Parra-Guillen Z, Kloft C. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer . Int J Clin Pharmacol Ther 2016
19.09.2016Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
19.09.2016Int J Clin Pharmacol Ther 2016
Klopp-Schulze Lena, Jörger Markus, Wicha Sebastian G, Parra-Guillen Zinnia P, Kloft Charlotte
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Jörger M, Behringer D, Ko Y, Hilger R, Roessler M, Kloft C, Henrich A, Moritz B, Miller M, Salamone S, Kopp H, Mayer F, von Pawel J, Kraff S, Fischer J, Eberhardt W, Gauler T, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
08.08.2016Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
08.08.2016Ann Oncol 2016; 27:1895-902
Jörger Markus, Behringer D M, Ko Y-D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Kopp H-G, Mayer F, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
28.07.2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
28.07.2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Jörger M, Finn S, Cuffe S, Byrne A, Gray S. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets 2016; 20:1339-1356.
11.07.2016The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
11.07.2016Expert Opin Ther Targets 2016; 20:1339-1356
Jörger Markus, Finn Stephen P, Cuffe Sinead, Byrne Annette T, Gray Steven G
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Warschkow R, Gueller U, Tarantino I, Cerny T, Schmied B, Thürlimann B, Jörger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
01.06.2016Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
01.06.2016Ann Surg 2016; 263:1188-98
Warschkow Rene, Gueller Ulrich, Tarantino Ignazio, Cerny Thomas, Schmied Bruno, Thürlimann Beat, Jörger Markus
A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
Warschkow R, Cerny T, Schmied B, Gueller U, Thürlimann B, Jörger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
17.05.2016A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
17.05.2016Br J Cancer 2016; 115:80-4
Warschkow Rene, Cerny Thomas, Schmied Bruno, Gueller Ulrich, Thürlimann Beat, Jörger Markus
Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology
Shao S, Guo T, Gross V, Lazarev A, Koh C, Gillessen Sommer S, Jörger M, Jochum W, Aebersold R. Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. J Proteome Res 2016; 15:1821-9.
10.05.2016Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology
10.05.2016J Proteome Res 2016; 15:1821-9
Shao Shiying, Guo Tiannan, Gross Vera, Lazarev Alexander, Koh Ching Chiek, Gillessen Sommer Silke, Jörger Markus, Jochum Wolfram, Aebersold Ruedi
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
15.04.2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
15.04.2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus
61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Baty F, Jörger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
15.04.201661PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
15.04.2016J Thorac Oncol 2016; 11:S81
Baty Florent, Jörger Markus, Früh Martin, Brutsche Martin
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
Hager S, Ackermann C, Jörger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016; 27:975-84.
06.04.2016Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
06.04.2016Ann Oncol 2016; 27:975-84
Hager S, Ackermann C J, Jörger Markus, Gillessen S, Omlin Aurelius
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Hamzic S, Wenger N, Froehlich T, Jörger M, Aebi S, Largiader C, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016
22.03.2016The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
22.03.2016Pharmacogenomics J 2016
Hamzic S, Wenger N, Froehlich T K, Jörger Markus, Aebi S, Largiader C R, Amstutz U
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8
02.01.2016Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
02.01.2016Cancers (Basel) 2016; 8
Crombag Marie-Rose B S, Jörger Markus, Thürlimann Beat, Schellens Jan H M, Beijnen Jos H, Huitema Alwin D R
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
11.12.2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
11.12.2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry
Shao S, Guo T, Koh C, Gillessen Sommer S, Jörger M, Jochum W, Aebersold R. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. Proteomics 2015; 15:3711-21.
10.09.2015Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry
10.09.2015Proteomics 2015; 15:3711-21
Shao Shiying, Guo Tiannan, Koh Chiek Ching, Gillessen Sommer Silke, Jörger Markus, Jochum Wolfram, Aebersold Ruedi
Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
Marsico J, Rodriguez R, Müller J, Jörger M. Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. J Cancer Res Ther 2015; 11:647.
01.07.2015Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
01.07.2015J Cancer Res Ther 2015; 11:647
Marsico Jennifer Gibbons, Rodriguez Regulo, Müller Joachim, Jörger Markus
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015
12.03.2015Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
12.03.2015Cancer Chemother Pharmacol 2015
Kraff Stefanie, Nieuweboer Annemieke J M, Mathijssen Ron H J, Baty Florent, de Graan Anne-Joy, van Schaik Ron H N, Jaehde Ulrich, Jörger Markus
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Jörger M, van Schaik R, Becker M, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015
10.03.2015Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
10.03.2015Prostate Cancer Prostatic Dis 2015
Jörger Markus, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer Silke, Rothermundt Christian
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Guo T, Jochum W, Jörger M, Gillessen Sommer S, Blum L, Collins B, Rosenberger G, Röst H, Wolski W, Gillet L, Koh C, Kouvonen P, Aebersold R. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21:407-13.
02.03.2015Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
02.03.2015Nat Med 2015; 21:407-13
Guo Tiannan, Jochum Wolfram, Jörger Markus, Gillessen Sommer Silke, Blum Lorenz C, Collins Ben C, Rosenberger George, Röst Hannes L, Wolski Witold E, Gillet Ludovic C, Koh Ching Chiek, Kouvonen Petri, Aebersold Ruedi
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
13.02.2015Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
13.02.2015Cancer Chemother Pharmacol 2015; 75:763-72
Jörger Markus, Beijnen J H, Cerny Thomas, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P H M, Doodeman V D, Cats A, Boot H, Huitema A D R, Schellens J H M
Metabolism of the taxanes including nab-paclitaxel
Jörger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014:1-12.
14.11.2014Metabolism of the taxanes including nab-paclitaxel
14.11.2014Expert Opin Drug Metab Toxicol 2014:1-12
Jörger Markus